The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa

Endocrine Journal

Volumn 54, Issue 6, 2007, Pages 953-959

  Ohwada, Rina ^a   Hotta, Mari ^b   Sato, Kanji ^a   Shibasaki, Tamotsu ^c   Takano, Kazue ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NATIONAL GRADUATE INSTITUTE FOR POLICY STUDIES   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Anorexia nervosa; Estradioll; Insulin like growth factor I (IGF I); Osteoporosis; Osteoprotegerin (OPG); Receptor activator of nuclear factor B ligand (RANKL)

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; LEPTIN; LIOTHYRONINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SOMATOMEDIN C;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; ARTICLE; BODY MASS; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN DEFICIENCY; FEMALE; HUMAN; MALNUTRITION; OSTEOLYSIS; OSTEOPOROSIS;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; ANOREXIA NERVOSA; BONE AND BONES; BONE DENSITY; CALCIUM; COLLAGEN TYPE I; ESTRADIOL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PEPTIDES; PHOSPHATES; RANK LIGAND; STATISTICS, NONPARAMETRIC; TRIIODOTHYRONINE;

EID: 40449113989     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K07-034     Document Type: Article

References (27)

1. Mehler S (2003) Osteoporisis in anorexia nervosa: Prevention and treatment. Int J Eat Disord 33: 113-126.
2. Mistra M, Klibanski A (2002) Evaluation and treatment of low bone density in anorexia nervosa. Nutr Clin Care 5/6: 298-308.
3. Munoz MT, Argente J (2002) Anorexia nervosa in female adolescents: endocrine and bone mineral density disturbances. European Journal of Endocrinology 147: 275-286.
4. Hotta M, Shibasaki T, Sato K, Demura H (1998) The importance of body weight history in the occurrence and recovery of osteoporosis in patients with anorexia nervosa: evaluation by dual X-ray absorptiometry and bone metabolic markers. European Journal of Endocrinology 139: 276-283.
5. Hotta M, Fukuda I, Sato K, Hizuka N, Shibasaki T, Takano K (2000) The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) 1, and serum IGF-binding protein levels in patients with anorexia nervosa. J Clin Endocrinol Metab 85: 200-206.
6. Heer M, Mika C, Grzella I, Drummer C, Herpertz-Dahlmann (2002) Changes in bone turnover in patients with anorexia nervosa during eleven weeks of inpatient dietary treatment. Clinical Chemistry 48: 754-760.
7. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Bonnet T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 18: 309-319.
8. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliot R, Colombero A, Elliot G, Sclly S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
9. Yasuda H, Shima N, Yamaguchi N, Kinosaki M, Mochizuki S, Yano K, Goto M, Tsuda A, Morinaga T, Higashio K, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor identical to TRANCE/RANKL. Cell Biology 95: 3597-3602.
10. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140: 4367-4370.
11. Saika M, Inoue D, Kibo S, Matsumoto T (2001) 17 beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 142: 2205-2012.
12. Bord S, Ireland DC, Beavan SR, Compston JE (2003) The effect of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. BONE 32: 136-141.
13. Liao EY, Luo XH, Su X (2002) Comparison of the effects of 17?-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast like cells. J Endocrinol Invest 25: 785-790.
14. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle W (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111: 1221-1230.
15. Crisafulli A, Altavilla D, Squadrito G, Romeo A, Adamo E, Marini R, Inferrera M, Marini H, Bitto A, D'anna R, Corrado F, Bartolone S, Frisina N, Squadrito F (2004) Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor κB ligand-osteoprotegerin system in early postmenopausal women. J Clin Endocrinol Metab 89: 188-192.
16. Misra M, Soyka L, Miller K, Herzog D, Grinspoon S, Chen D, Neubauer G, Klibanski A (2003) Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 88: 3816-3822.
17. Kahl K, Rudolf S, Dibbelr L, Stoeckelhuber B, Gehl H, Hohagen F, Schweiger U (2004) Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. Osteoporosis International 10.1007: 1711-1715.
18. Jung K, Lein M, Hosslin K, Grosse A, Roth S, Possinger K, Luftner D (2002) Osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) in the serum of healthy adults. Int J Biol Markers 17: 177-181.
19. Hofbauer LC, Scoppet M, Schuller P, Viereckt V, Chist M (2004) Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol 60: 214-219.
20. Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D (2003) Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turners' syndrome and rheumatoid arthritis. Clin Endocrinol (Oxf) 60: 87-91.
21. Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Names MS, Marcus R, Holloway L, Beamer WG, Rosen CJ (2002) IGF-1 regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87: 4273-4279.
22. Ueland T, Odgren PR, Yndestad A, Godang K, Schreiner T, Marks SC, Bollerslev J (2003) Growth hormone substitution increases gene expression of members of the IGF family in cortical bome from women with adult onset growth hormone deficiency-relationship with bone turn-over. BONE 33: 638-645.
23. Grigorie D, Neacsu E, Marinescu M, Popa O (2004) Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. Rom J Intern Med 41: 409-415.
24. Holloway WR, Collier FM, Aitken C, Myers D, Hodge J, Malakellis M, Goigh TJ, Colloer GR, Nicholson GC (2002) Leptin Inhibits osteoclast generation. J Bone Miner Res 17: 200-209.
25. Thomas T, Burguera B (2002) Is leptin the link between fat and bone mass? J Bone Miner Res 17: 1563-1569.
26. Buxton EC, Yao W, Lane NE (2004) Changes in rerum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 89: 3332-3336.
27. Seck T, Diel I, Bismar H, Zeigler R, Pfeilschifter J (2001) Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. Eur J Endocrinol 145: 199-205.